Related Experiment Video
Updated: Jul 25, 2025
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
Ilaria Colombo1, Katherine Karakasis2, Sneha Suku2
1Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Via A. Gallino, 6500 Bellinzona, Switzerland.
Abstract:
A deep understanding of the tumor microenvironment and the recognition of tumor-infiltrating lymphocytes as a prognostic factor have resulted in major milestones in immunotherapy that have led to therapeutic advances in treating many cancers. Yet, the translation of this knowledge to clinical success for ovarian cancer remains a challenge. The efficacy of immune checkpoint inhibitors as single agents or combined with chemotherapy has been unsatisfactory, leading to the exploration of alternative combination strategies with targeted agents (e.g., poly-ADP-ribose inhibitors (PARP)and angiogenesis inhibitors) and novel immunotherapy approaches. Among the different histological subtypes, clear cell ovarian cancer has shown a higher sensitivity to immunotherapy. A deeper understanding of the mechanism of immune resistance within the context of ovarian cancer and the identification of predictive biomarkers remain central discovery benchmarks to be realized. This will be critical to successfully define the precision use of immune checkpoint inhibitors for the treatment of ovarian cancer.
Insights
Despite advances in cancer immunotherapy, ovarian cancer treatment remains challenging. Further research into immune resistance and biomarkers is crucial for effective immune checkpoint inhibitor therapy in ovarian cancer.
Area of Science:
- Oncology
- Immunology
- Gynecologic Oncology
Background:
- Immunotherapy has revolutionized cancer treatment, with tumor microenvironment and tumor-infiltrating lymphocytes recognized as key prognostic factors.
- Translating immunotherapy success to ovarian cancer has been challenging, with suboptimal responses to current immune checkpoint inhibitors and chemotherapy combinations.
Purpose of the Study:
- To explore alternative combination strategies for ovarian cancer immunotherapy, including targeted agents like poly-ADP-ribose (PARP) inhibitors and angiogenesis inhibitors.
- To investigate novel immunotherapy approaches and understand the mechanisms of immune resistance in ovarian cancer.
- To identify predictive biomarkers for enhancing the efficacy of immune checkpoint inhibitors in ovarian cancer treatment.
Main Methods:
- Review of current immunotherapy strategies and their limitations in ovarian cancer.
- Analysis of emerging combination therapies involving targeted agents and novel immunotherapies.
- Exploration of histological subtype-specific responses, noting higher sensitivity in clear cell ovarian cancer.
Main Results:
- Clear cell ovarian cancer subtypes demonstrate increased sensitivity to immunotherapy compared to other subtypes.
- Current immune checkpoint inhibitors show limited efficacy as monotherapy or in combination with chemotherapy.
- Alternative strategies combining targeted agents and novel immunotherapies are under investigation.
Conclusions:
- A deeper understanding of ovarian cancer's immune resistance mechanisms is essential for therapeutic advancement.
- Identification of predictive biomarkers is critical for the precise application of immune checkpoint inhibitors.
- Tailoring immunotherapy strategies based on histological subtypes and resistance mechanisms holds promise for improved ovarian cancer treatment outcomes.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy